These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 32584677)

  • 21. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
    Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I
    Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economic burden of metastatic pancreatic cancer.
    Malangone-Monaco E; Doleh Y; Cole A; Noxon V; Antico G; Pishvaian MJ
    Pancreatology; 2020 Oct; 20(7):1434-1441. PubMed ID: 32967794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
    Franco F; Camara JC; Martín-Valadés JI; López-Alfonso A; Marrupe D; Gutiérrez-Abad D; Martínez-Amores B; León A; Juez I; Pérez M; Royuela A; Ruiz-Casado A
    Clin Transl Oncol; 2021 Apr; 23(4):812-819. PubMed ID: 32857340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
    Latenstein AEJ; Mackay TM; Creemers GJ; van Eijck CHJ; de Groot JWB; Haj Mohammad N; Homs MYV; van Laarhoven HWM; Molenaar IQ; Ten Tije BJ; de Vos-Geelen J; Besselink MG; van der Geest LGM; Wilmink JW;
    Acta Oncol; 2020 Jun; 59(6):705-712. PubMed ID: 32056483
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
    Chun JW; Lee SH; Kim JS; Park N; Huh G; Cho IR; Paik WH; Ryu JK; Kim YT
    BMC Cancer; 2021 May; 21(1):537. PubMed ID: 33975561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
    Kharat AA; Nelson R; Au T; Biskupiak J
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1367-1375. PubMed ID: 34595948
    [No Abstract]   [Full Text] [Related]  

  • 30. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
    Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
    Pancreatology; 2020 Sep; 20(6):1131-1138. PubMed ID: 32739267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
    Assenat E; de la Fouchardière C; Portales F; Ychou M; Debourdeau A; Desseigne F; Iltache S; Fiess C; Mollevi C; Mazard T
    ESMO Open; 2021 Dec; 6(6):100318. PubMed ID: 34837745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
    Smyth EN; Bapat B; Ball DE; André T; Kaye JA
    Clin Ther; 2015 Jun; 37(6):1301-16. PubMed ID: 25907619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
    Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
    Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
    Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
    Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
    Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
    J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
    [No Abstract]   [Full Text] [Related]  

  • 36. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
    Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
    Norden AD; Korytowsky B; You M; Kim Le T; Dastani H; Bobiak S; Singh P
    J Manag Care Spec Pharm; 2019 Apr; 25(4):428-436. PubMed ID: 30917077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
    Zaibet S; Hautefeuille V; Auclin E; Lièvre A; Tougeron D; Sarabi M; Gilabert M; Wasselin J; Edeline J; Artru P; Bechade D; Morin C; Ducoulombier A; Taieb J; Pernot S
    Br J Cancer; 2022 Jun; 126(10):1394-1400. PubMed ID: 35094032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
    Abrams TA; Meyer G; Meyerhardt JA; Wolpin BM; Schrag D; Fuchs CS
    Oncologist; 2017 Aug; 22(8):925-933. PubMed ID: 28476943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
    Kang J; Hwang I; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Hong SM; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
    Invest New Drugs; 2018 Aug; 36(4):732-741. PubMed ID: 29616439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.